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Nanoparticles functionalized with multiple ligands can be programmed to bind biological tar-
gets depending on the receptors they express, providing a general mechanism exploited in various
technologies, from selective drug-delivery to biosensing. For binding to be highly selective, ligands
should exclusively interact with specific targeted receptors, because formation of bonds with other,
untargeted ones would lead to non-specific binding and potentially harmful behaviour. This poses a
particular problem for multivalent nanoparticles, because even very weak bonds can collectively lead
to strong binding. A statistical mechanical model is used here to describe how competition between
different receptors together with multivalent effects can be harnessed to design ligand-functionalized
nanoparticles insensitive to the presence of untargeted receptors, preventing non-specific binding.
Cells typically present a large variety of receptors on
their surface, providing a “biological barcode” to distin-
guish cells of different type or in different states, e.g.
healthy vs sick [1]. This idea is at the basis of a widely
used drug-delivery strategy in nanomedicine, which ex-
ploits nanoparticles functionalized with multiple ligands
that recognize specific receptors, whose expression is
known to be associated to a disease [2, 3]. In the same
way, various nanoparticles-based biosensing applications
also exploit ligand-receptor binding to detect the pres-
ence of specific targets [4].
For selective targeting based on ligand-receptor recogni-
tion, strategies are required to distinguish targets based
not only on the type of receptors present, but also on
their expression level. The latter is particularly impor-
tant for those diseases, including certain cancers, where
healthy and sick cells do not present different receptors,
but rather over-regulate one (or few) of them [2]. For
both targeting scenarios it has been shown that nanopar-
ticles displaying multiple binding ligands can better dis-
criminate targets compared to monovalent drugs [3, 5–
7]. However, this is not always the case, and under-
standing the conditions leading to enhanced selectiv-
ity, or loss of it, is an important step for rational de-
sign. The mechanism behind enhanced selectivity of mul-
tivalent nanoparticles towards receptor over-expression,
also dubbed “super-selectivity”, was first elucidated by
Martinez-Veracoecha and Frenkel [7]. These authors used
both analytical theory and Monte Carlo simulations to
show how such effect could be well understood consid-
ering the statistical mechanics of multivalent binding.
Later on, Dubacheva et al [8, 9] extended their theory
to the case of targeting using multivalent polymers. In
these latter works, extensive comparison to experimen-
tal results proved how such theory could correctly de-
scribe various trends observed, and thus be used to de-
sign targeting applications [9]. Previous works on the
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Figure 1: Binding of a multivalent nanoparticle (blue sphere,
ligands in red) to a cell surface (pink) expressing certain re-
ceptors. Ligands specifically target orange receptors, (over-
)expressed in a disease state. Green receptors are other recep-
tors not related to it. a)-b) ideal scenario: Ligands only bind
to targeted receptors, and nanoparticles will adsorb when
these are expressed above a certain threshold (a), but not
below (b) [7]. c,d) realistic scenario: Ligands see both tar-
geted and untargeted receptors, binding the latter weakly.
Multiple weak bonds can still lead to non-specific adsorption
even when targeted receptors are not over-expressed (c). This
problem can be alleviated using “protective” receptors (light
green) directly coated on the nanoparticle (d). If these form
stronger bonds compared to untargeted receptors, selective
binding is restored.
super-selectivity of multivalent nanoparticles focused on
model systems, where only a single type of receptor is
considered. Cells, however, express various types, most
of which associated to normal function. This observation
naturally leads to the question: Can these other receptors
affect targeting selectivity (see Fig. 1 for reference)? Due
to the physics of their interaction, this is particularly im-
portant for multivalent constructs. Consider for example
a nanoparticle whose ligands are optimized to target one
specific receptor type. To be more precise, this means
that the strength of a bond with such receptor is higher
compared to any other. The problem lies in the fact that
due to multivalency weak single bonds to untargeted re-
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2ceptors can still collectively provide a high binding en-
ergy [10]. This in turn can drive non-specific adsorption
of the nanoparticles to cells which do not express the
targeted receptors. In the context of drug-delivery, this
scenario would lead to higher toxicity, whereas in biosens-
ing it would cause false positives. In this Letter, we com-
bine a recent theory of ligand-receptor-mediated inter-
actions [11, 12] with the model developed by Martinez-
Veracoecha and Frenkel for nanoparticles adsorption (de-
tails in the SI) to quantify this scenario, and propose a
general solution.
Briefly, the Martinez-Veracoecha and Frenkel model de-
scribes adsorption of ligand-functionalized nanoparticles
from a solution to a target displaying multiple receptors.
Expanding this model to account for multiple receptor
types, i.e. targeted and untargeted, the adsorption prob-
ability θ reads:
θ =<
zq
(
NL, NT, NU, {∆˜GX}
)
1 + zq
(
NL, NT, NU, {∆˜GX}
) ><NT>,<NU> .
(1)
Subscripts L, T, U refer to ligands, targeted and untar-
geted receptors, respectively. Hence in Eq. 1 NX=L,T,U
is the number of ligands and targeted or untargeted re-
ceptors, whereas ∆˜GX is the bond free energy ∆˜G of a
ligand with receptor of type X = T,U (we always con-
sider energies to be scaled by the thermal energy kBT ,
where kB is Boltzman’s constant and T temperature).
<><NT>,<NU> indicates an average over two Poisson
distributions, one over the number of targeted recep-
tors, with average < NT >, and one over the number
of untargeted receptors, with average < NU >. Further-
more, q is the ratio between the partition function of
the nanoparticle in the bound vs unbound state and z
is the nanoparticles’ activity in the bulk solution, pro-
portional to nanoparticles’ number density and binding
volume. For ease of discussion, we focus here on the case
of only two receptor types. However, it can be shown that
any arbitrary distribution of untargeted receptors can be
mapped onto, or be bound by, a two-types model with
an effective number of receptors. For this reason, results
do not change upon considering more complex scenarios
(see the SI).
Eq. 1 has the form of the Langmuir adsorption isotherm.
All multivalent effects enter via q, which can be written
as:
q = e−(F˜
surf
att −F˜bulkatt ) − 1, (2)
where F˜att indicates the free-energy due to bond forma-
tion, and F˜ surfatt , F˜
bulk
att are its values when the nanopar-
ticle is either adsorbed on the target surface or in the
bulk solution, respectively. A formal definition of F˜att,
which is always negative or at most zero when no bonds
can form, is given in [13]. The −1 term in Eq. 2 takes
into account the constraint that a particle must have at
least one bond with the surface to be bound. Note that
F˜ bulkatt is zero if nanoparticles can only form bonds with
the surface. However, this is not true when intra-particle
bonds occur, an important fact exploited later. Given
Eqs. 1,2, the adsorption probability θ can be calculated
once F˜att is known for the system of ligand-receptor pairs
considered. This is provided by the formula [11]:
F˜att =
∑
i
log pi +
1
2
(1− pi) (3)
where i is an index running over all possible binders,
i.e. ligands or receptors, and pi is the probability that
such binder is unbound, given by the solution of a set of
non-linear coupled equations:
pi +
∑
j
pipjχij = 1, (4)
where χij = exp
(
−∆˜Gij
)
. In Eq.4, χij is the strength
of a bond for a specific ligand-receptor pair i, j and ∆˜Gij
is the corresponding bond energy. The index j runs over
all possible binding partners of i, and there are Nbinder
coupled equations, one for each binder in the system.
This set of equations must be solved numerically [12], but
analytical expressions from a mean-field model providing
a qualitative picture will also be discussed (see the SI).
We illustrate our results by calculating two key quantities
describing binding selectivity. The first is the adsorption
probability θ, given by Eq. 1. The second is the so-called
selectivity parameter α [7], defined here as:
α(< NT >,< NU >) =
∂ log θ
∂ log < NT >
|<NT>,<NU> (5)
which gauges nanoparticles’ ability to tell apart bind-
ing sites with different numbers of targeted receptors
< NT >. More precisely, for α > 1 the adsorption prob-
ability raises super-linearly, approaching an ideal on-off
behaviour where particles bind exclusively if receptors
concentration is higher than a certain threshold. On the
opposite side, α < 1 indicates appreciable adsorption for
a broad range of receptors concentrations, α = 0 being
indiscriminate adsorption.
Fig 2 illustrates the effect of non-specific interactions
for nanoparticles differing in either the number of tar-
geting ligands NL or the bond strength with untargeted
receptors. The rightmost panels in the top figure repre-
sent the “ideal” behaviour one would observe when lig-
ands do not interact at all with untargeted receptors (see
Fig. 1a). In this case, appreciable adsorption is observed
only above a certain number of targeted receptors. When
the strength of untargeted bonds increases, the effect of
non-specific interactions rapidly increases too and par-
ticles also adsorb when this is not expected. In fact,
above a certain number of untargeted receptors appre-
ciable adsorption will occur even when the targeted re-
ceptors are completely absent, completely losing selec-
tivity. As can be inferred by comparing nanoparticles
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Figure 2: Top: Adsorption probability θ ( Eq. 1) as a function
of the number of targeted (NT) and untargeted (NU) recep-
tors. Results are reported for different number of ligands NL
and untargeted bonds energies ∆˜GU (the energy of a targeted
bond is ∆˜GT = −3). As the number of untargeted receptors
increases, their effect becomes stronger and nanoparticles ad-
sorb also when in the ideal case (rightmost panels), this would
not occur. This problem increases with higher valencies and
bond strengths (smaller ∆˜GU). Bottom: Maximum selectiv-
ity α achievable, Eq. 5, as a function of NU.
with different number of ligands, this problem becomes
more prominent as their valency increases. The observed
behaviours can be qualitatively captured within a mean-
field description, which provides the simple expression:
q = (1 + γT + γU)
NL − 1; γx = Nx exp
(
−∆˜GX
)
. (6)
Given the dependence of θ on q (Eq. 1) appreciable ad-
sorption is expected whenever q >∼ z−1. From Eq. 6,
q increases with both the strength of untargeted recep-
tors and the number of ligands NL. Notably, this in-
crease is super-linear with respect to the number of un-
targeted receptors whenever the valency is higher than
one, predicting that selectivity will rapidly deteriorate
for multivalent nanoparticles once interactions with un-
targeted receptors are accounted for. The same expres-
sion also shows that whenever the number of untar-
geted receptor is higher than an upper limit N limU =
exp(β∆GU)
[
(1/z + 1)1/NL − 1], adsorption occurs even
in the complete absence of any targeted receptor.
In most applications, multivalency have been exploited
to increase the binding strength to a specific target using
singularly weak-bonds. For this use, the binding strength
enhancement has the positive effect to decrease the de-
tection level of the target. However, what we show here is
that exactly this same feature can provide enough bind-
ing strength to drive adsorption to the wrong targets due
to the formation of many weak bonds with untargeted re-
ceptors. Hence, when considering targeting applications,
care must be taken with multivalent architectures.
The analysis of the selectivity parameter α, reported in
Fig 2, provides further insights into the extent of this
problem. More precisely, for each value of < NU > we
consider the maximum α achievable within the < NT >
range, which provides an upper bound to the selectiv-
ity of the system. When only targeted receptors are
present, it was shown [7] that multivalent nanoparticles
can achieve almost optimal on-off behaviour, i.e. α > 1
around some value of NT. In practice, this means that
nanoparticles adsorb only when the number of receptors
is higher that NT, and never below. This so-dubbed
“super-selectivity” is a specific feature of multivalent
particles that, importantly, monovalent ones can never
achieve [7–9]. It is this advantage that suggest the use of
multivalent nanoparticles for selective targeting, consid-
ering that in various diseases cells simply over-regulate
the expression of certain receptors rather than express-
ing a mutated form that could be distinguished using an
optimized ligand. Considering the effect of untargeted re-
ceptors, however, the picture changes. As shown in Fig 2,
the super-selective regime can completely disappear, and
indeed under broad conditions multivalent particles will
perform worse then monovalent ones. As for the case of
θ, the observed trends are a decrease in selectivity with
increasing valency and increasing strength of the bonds
to untargeted receptors, as should be expected.
Given the problems previously discussed and the trends
observed, a question arises: Can we simply optimize lig-
ands to reduce non-specific interactions? The answer to
this question is indeed positive, but one must solve a com-
plex optimization problem. Ligands optimization is usu-
ally run to find the one with the highest possible binding
strength for a given receptor [4]. This is a perfectly valid
strategy if the aim is to decrease their detection thresh-
old. This strategy, however, does not necessarily improve
the ability of ligands to discern between different receptor
types, which requires increasing the gap in the strength
between the targeted receptor and every other possible
receptor type, a much harder optimisation problem. Ad-
ditionally, although increasing the strength of the bond
with targeted receptors improve their detection , it also
negatively impacts the possibility to tell apart targets
with different expression levels, since stronger bonds lead
to appreciable adsorption for a broader range of receptors
densities, as proved in [7]. In practice, ligands optimiza-
4tion is complicated by these contrasting requirements.
The problems previously described arise from the very
nature of multivalent interactions, and thus will affect
multivalent constructs regardless of their exact specifics.
Inspired by previous work on the self-assembly of ligand-
receptor coated particles [14], we propose here a function-
alization scheme where competition between different re-
ceptors is exploited to achieve binding properties which
are insensitive to the presence of untargeted receptors,
and thus restore selectivity.
In this “protected” scheme, multivalent particles are
functionalized with both ligands and receptors that can
bind to them (see Fig.1 d). From here on, the latter
will be called “protecting” receptors. The effects of such
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Figure 3: Top: As in Fig. 2 but for protected nanoparti-
cles. Compared to normal particles, non-specific adsorption
is strongly reduced. Bottom: Comparison of the maximum se-
lectivity αmax (Eq. 5) between protected and normal nanopar-
ticles, continuous and dashed lines, respectively. Colours de-
note different number of ligands (5, blue and 10, red). Pro-
tected nanoparticles show overall higher selectivity, and dis-
play super-selective behaviour, max(α) > 1, in regions where
normal particles would perform even worse than monovalent
ones. ∆˜GT = −3, as in Fig. 2, and ∆˜GP = ∆˜GT.
design, reported in Fig. 3, are evident comparing with
the previous results for normal nanoparticles in Fig. 2.
First, the amount of untargeted receptors that protected
particles can bear without affecting adsorption is greatly
increased, and in fact ideal behaviour is observed for al-
most all receptors concentrations and binding strengths.
Moreover, super-selective adsorption ( α > 1) is recov-
ered in scenarios where the typical multivalent archi-
tecture shows sub-optimal behaviour even compared to
monovalent particles. Furthermore, no strong deteriora-
tion of selectivity with increasing valency is observed for
the protected design, whose properties are almost inde-
pendent on valency.
Quantifying these effects requires a statistical mechanical
description to properly account for the relative weight of
all possible binding configurations, but they can be qual-
itatively understood using a simple microscopic picture.
Ligands bound to a protecting receptor cannot concur-
rently bind those on the surface. However, the system
is in a dynamic equilibrium where bonds continuously
break and form, and on average bonds with surface re-
ceptors will occur if their formation is thermodynamically
favourable compared to those with protecting receptors.
This is typically so only for bonds with the targeted re-
ceptors for which ligands are optimised to have a high
binding strength, not for others. It is indeed this mech-
anism that leads to high selectivity for this scheme. The
equilibrium behind it is controlled by the relative energies
of these bonds, ∆˜GT− ∆˜GP and ∆˜GU− ∆˜GP (P mean-
ing protecting receptors). It also depends on the number
of ligands, protecting, and surface receptors, since their
quantity affect the relative entropy of binding. In fact,
within a mean field model, one could simply regard the
number of ligands or receptors as an additional energy
contribution of ∆˜Gx = − logNx to be added to the true
bond energy. The microscopic picture we presented easily
describes other trends in this system, such as the increase
in selectivity with increasing number of protecting recep-
tors, and with stronger protecting bonds (see the Sup-
plementary Information). It also explains the increase
in the selectivity parameter α for the protected scheme:
protecting bonds shift the effective bond energy without
reducing the difference between targeted and untargeted
receptors. In this way, they boosts super-selectivity be-
cause they provide a mechanism to make targeted bonds
effectively weaker and weaker without however increas-
ing the contribution of non-specific interactions, which
would instead come into play with a normal design. In
practice, protecting receptors allow to reduce a realistic
multi-receptor scenario to an ideal one where only tar-
geted receptors are present.
Before concluding, we discuss a possible practical
realisation of this “protected” architecture. Although
this scheme is very general and various solutions can be
envisaged, we would like to focus on a specific system
which we deem very promising, colloids coated with
DNA (DNACCs). Protected DNACCs have already
been experimentally implemented to study self-assembly
[15, 16]. This system, where DNA acts both as ligand
and receptor, represents in itself a very interesting and
powerful solution. DNACCs are already under intense
investigation in drug-delivery and biosensing [17], but
even more importantly DNA can bind to a large variety
5of molecules. Short DNA strands, so-called “aptamers”,
are widely used as targeting ligands for proteins, and a
wide literature exists regarding their optimization [4].
Such knowledge combined with extensively validated
models to calculate DNA-DNA binding energies [18, 19]
can be used as a general and powerful platform for the
design of protected targeting constructs. One simple
way to implement the proposed scheme would be to
functionalize nanoparticles with both the targeting
aptamer and its complementary DNA sequence, which
would act as its protecting receptor. DNA would also
provide an easy way to tune the strength of protecting
bonds, by simply changing the nucleotides sequence of
protecting strands.
In conclusion, in this Letter we addressed selective
targeting using multivalent nanoparticles via a statis-
tical mechanical model. This was done by combining
previous results [7, 11] in a unified theory, allowing to
unravel the physics behind non-specific binding arising
from the presence of multiple receptor types. We
showed how multivalent particles are more sensitive to
non-specific binding compared to monovalent ones, and
that their selectivity rapidly deteriorates in presence
of different receptors types. To solve this problem, we
proposed and justified a simple design principle: Beside
targeting ligands, nanoparticles should also be coated
with protecting receptors able to bind them, shielding
their interactions with untargeted receptors. We showed
that this mechanism prevents non-specific adsorption,
and increases selectivity under conditions where typical
nanoparticles would not work. Protecting receptors have
been previously shown to enhance the self-assembly
kinetics of DNACCs [14], a very different problem from
the one treated here. They could also similarly prove
beneficial for other soft-matter systems, e.g. in patchy
particles on substrates when competing interactions are
present [20]. We finally stress that, in the context of
nanomedical applications, the problem and the solution
proposed here do not apply only to nanoparticles,
or to cells targeting. Instead, they emerge whenever
multivalent constructs are used, e.g. in functionalized
polymers or surfaces that recognize specific biomarkers
via multiple binding sites.
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